Synonyms: inhibitor 15d [PMID: 18314943] | LY-2157299 | LY2157299
Compound class:
Synthetic organic
Comment: Galunisertib is a first-in-class investigational inhibitor of the receptor tyrosine kinase, growth factor-β receptor type I (TGFβRI) [1-2]. It is being evaluated as a novel anticancer agent.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Galunisertib is being evaluated in Phase 3 clinical trials for the treatment of various solid tumours (including those of the liver, prostate, pancreas and brain) as well as myelodysplastic syndromes. Click here to link to a full list of galunisertib trials registered with ClinicalTrials.gov. |